Oral psoriatic arthritis treatment accepted for NHS use

Apremilast (Otezla) has been approved by NICE for treating psoriatic arthritis.

In patients with psoriatic arthritis, apremilast produced significantly higher ACR20 response rates at 16 weeks than placebo. | SCIENCE PHOTO LIBRARY
In patients with psoriatic arthritis, apremilast produced significantly higher ACR20 response rates at 16 weeks than placebo. | SCIENCE PHOTO LIBRARY

Apremilast, alone or in combination with DMARDs, is recommended as an option for treating active psoriatic arthritis in adults with 3 or more tender joints and 3 or more swollen joints who have not responded to adequate trials of at least 2 standard DMARDs, given either alone or in combination.

Approval is conditional on the company providing apremilast with the discount agreed in the patient access scheme.

Prescribers should stop apremilast at 16 weeks if the psoriatic arthritis has not shown an adequate response according to Psoriatic Arthritis Response Criteria (PsARC), defined as an improvement in at least 2 of the 4 criteria (including joint tenderness or swelling score) with no worsening in any criteria. If a Psoriasis Area and Severity Index (PASI) 75 response is achieved, a dermatologist should decide whether to continue treatment based on skin response.

Treatment of patients already receiving apremilast who do not meet the above criteria may be continued until they and their NHS clinician consider it appropriate to stop.

In November, apremilast was approved by NICE for the treatment of psoriasis. The drug inhibits phosphodiesterase 4, causing elevation of intracellular cAMP levels and in turn downregulating the inflammatory response by modulating the expression of inflammatory cytokines including TNF.


Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS bulletins

News and updates straight to your inbox.

Prescribing Update: Fortnightly news bulletin
Alert:
Urgent prescribing updates
Spotlight: Disease-themed monthly round-up

Sign me up

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases